Overview
Find Therapeutics, clinical-stage biopharmaceutical company, announced initiation of dosing in its phase 1 clinical study of FTX-101 in healthy volunteers. FTX-101 is a first-in-class therapeutic peptide that modulates the Plexin A1/Neuropilin 1 transmembrane receptor complex in the brain to promote remyelination. Following completion of the phase 1 clinical study, Find plans to investigate the use of FTX-101 in individuals with chronic optic neuropathy – a long-term condition due to demyelination in the visual tracts of the brain and optic nerve, with serious effects on visual acuity and perception.
The Phase 1 Study
- The phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics of FTX-101 when administered in healthy volunteers.
- The study is being initiated after the US Food and Drug Administration authorized initiation of the study earlier this year.
- The clinical study consists of two parts: -
Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study comprised of 40 subjects receiving FTX-101 or placebo while Part 2 is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study that will enroll 24 subjects receiving FTX-101 or placebo.
Beginning of This Study
- The initiation of this study is a significant milestone for both our company and individuals who suffer with chronic optic neuropathy.
- In this study, we will build on the large body of preclinical evidence demonstrating FTX-101’s effects in models of autoimmune disease.
- A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with chronic optic neuropathy.
- We look forward to sharing data from this study in the first half of 2025.
About FTX-101
- Find’s lead compound, FTX-101, is a first-in-class remyelinating agent that aims to restore vision to people suffering from chronic optic neuropathy.
- FTX-101 is a rationally designed therapeutic peptide that targets Plexin A1 and Neuropilin 1, a receptor complex present in the brain that has been shown to be involved in the migration and differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes.
- Compelling preclinical data for FTX-101 in demyelinating models show strong myelin repair activity.
About the Content: Find Therapeutics
- Find Therapeutics is clinical-stage biopharmaceutical company dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases.
- The company was launched in 2020 and is supported with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec and an exclusive license from SATT-Conectus and the University of Strasbourg on a technology and related know-how.
